The metabolic enzyme IL4I1 (Interleukin-4-Induced-1) promotes the spread of tumour cells and suppresses the immune system.

This was discovered by scientists at the German Cancer Research Center (DKFZ) and the Berlin Institute of Health (BIH).

The enzyme that activates the dioxin receptor is produced in large quantities by tumour cells.

In the future, substances that inhibit IL4I1 could open up new opportunities for cancer therapy.

The scientists have now published their results in the journal Cell.

Immunotherapies activate the body's own defence against tumours and are currently revolutionising cancer therapy.

Despite some groundbreaking successes, however, only a small number of patients benefit from the drugs currently available.

The teams led by Christiane Opitz and Martina Seiffert, both at the DKFZ, and Saskia Trump from BIH, investigated the molecular mechanisms by which tumours escape destruction by the immune system.

Their research results may provide important information for the development of new immunotherapy concepts.

The aryl hydrocarbon receptor (AHR) is also known as dioxin receptor because it mediates the toxic effect of dioxins.

However, not only toxins, but also the body's own metabolic products can activate the receptor.

An example of this are degradation products of the amino acid tryptophane, which we take in with our food as a building block of proteins.

Tumours use these metabolites to their advantage: They promote the mobility of cancer cells and weaken the immune response against tumours.

However, the metabolic pathways by which the relevant tryptophane degradation products are produced have not been sufficiently researched.

To find out more, the scientists systematically investigated in 32 different types of cancer which tryptophane-degrading enzymes are associated with an activation of the dioxin receptor.

One molecule in particular caught the scientists' eye: the enzyme IL4I1.

No other enzyme of the tryptophan metabolism was as strongly linked to an activation of the dioxin receptor as IL4I1: "The metabolites formed by IL4I1 bind to the dioxin receptor and activate it, which leads to the suppression of immune cells," explains Saskia Trump, BIH.

Of clinical interest is the observation that the survival probability of patients with gliomas, a type of malignant brain tumour, decreased when the enzyme was present in higher concentrations in these tumours.

In a mouse model for chronic lymphatic leukaemia (CLL), a type of blood cancer, IL4I1 was shown to promote cancer through its effects on the immune system.

"In animals that do not produce IL4I1 in the tumour environment due to genetic alterations, the immune system is significantly more successful in preventing the cancer from progressing," explains Martina Seiffert of DKFZ.

"IL4I1 has great potential as a target for drugs. So far, drugs that inhibit enzymes of the tryptophan metabolism have failed in clinical trials because the tumours did not respond to them. However, the role of IL4I1 has so far been disregarded and this enzyme has not yet been tested as a target molecule," said Christiane Opitz.

Source: German Cancer Research Center